Owners, management and financials
CVR: 37509736
Previous names: ApS STM nr. 4310, Renoguard ApS, AKI Therapeutics ApS
DKK 0
Gross profit
Net result: DKK -1,593,852,000
NIELS ERIK JESPERSEN HOLDING ApS (5-9,99%), Beier Holding ApS (10-14,99%)
4 more
CVR · view owners
Sigbjørn Georg Nielsen Kjærgård
Board: 3 members
CVR · view management
Active
Founded 1 March 2016
CVR · view overview
No headcount reported
Owner registered: Klaus Poulsen Holding ApS
CVR · 13/12/2024
View the full event history
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.
Selskabets formål er at udvikle repositonerede lægemidler samt dermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 0 | -1.6 mia. | 1.6 mia. | 551.9 mio. | - | |
| 202401/01/2024 – 31/12/2024 | 0 | -2 mio. | 2.2 mio. | 807 t. | - | |
| 202301/01/2023 – 31/12/2023 | 0 | -1.7 mio. | 2 mio. | 747 t. | - | |
| 202201/01/2022 – 31/12/2022 | 0 | -1.1 mio. | 3.3 mio. | 2.5 mio. | - | |
| 202101/01/2021 – 31/12/2021 | 0 | -1.5 mio. | 4.7 mio. | 3.6 mio. | - | |
| 202001/01/2020 – 31/12/2020 | - | 148 t. | 1.9 mio. | 115 t. | - | |
| 201901/01/2019 – 31/12/2019 | - | 28 t. | 933 t. | 52 t. | - | |
| 201801/01/2018 – 31/12/2018 | - | -5 t. | 144 t. | 24 t. | - | |
| 201701/01/2017 – 31/12/2017 | - | -13 t. | 34 t. | 29 t. | - | |
| 201601/03/2016 – 31/12/2016 | - | -8 t. | 48 t. | 42 t. | - |
Compared to 128 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of AKI Therapeutics A/S is 37509736.
The owners of AKI Therapeutics A/S include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS.
The management of AKI Therapeutics A/S consists of Sigbjørn Georg Nielsen Kjærgård.
The board of AKI Therapeutics A/S consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal.
In 2025, AKI Therapeutics A/S reported a gross profit of DKK 0.
AKI Therapeutics A/S was founded on 1 March 2016.
Claim this page to add your logo and social links. Free to get started.
AKI Therapeutics A/S has published its annual report for 2025. Revenue came to DKK 0, and the net result was DKK -1,593,852,000.
As of May 28, 2026, Troels Peter Troelsen has left the board of directors of AKI Therapeutics A/S.
AKI Therapeutics A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -1,960,091.
As of December 13, 2024, Klaus Poulsen Holding ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
As of November 6, 2024, DMZ HOLDING ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 15%.
AKI Therapeutics A/S has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -1,708,694.
As of June 13, 2024, Charlotte Pahl has joined the board of directors of AKI Therapeutics A/S.
As of October 5, 2023, FINANSMANAGEMENT ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
AKI Therapeutics A/S has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -1,117,346.
AKI Therapeutics A/S has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -1,523,621.
As of May 31, 2022, Troels Ring has left the board of directors of AKI Therapeutics A/S.
On May 31, 2022, the company changed its name from AKI Therapeutics ApS to AKI Therapeutics A/S.
AKI Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK -89,304, and the net result was DKK 148,172.
As of June 22, 2021, Troels Peter Troelsen has joined the board of directors of AKI Therapeutics A/S.
As of June 22, 2021, Christian Vinding Thomsen has joined the board of directors of AKI Therapeutics A/S.
As of June 22, 2021, Lars Otto Uttenthal has joined the board of directors of AKI Therapeutics A/S.
As of June 22, 2021, Troels Ring has joined the board of directors of AKI Therapeutics A/S.
As of September 28, 2020, Sigbjørn Georg Nielsen Kjærgård is registered as director of AKI Therapeutics A/S.
As of September 28, 2020, Torsten Bjørn has stepped down as director of AKI Therapeutics A/S.
AKI Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK -127,150, and the net result was DKK 27,968.
As of September 1, 2020, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of AKI Therapeutics A/S.
As of September 1, 2020, KALLERMANN REVISION A/S STATSAUTORISERET REVISIONSFIRMA has stepped down as auditor of AKI Therapeutics A/S.
As of August 17, 2020, BREGNERØDVEJ AUTO ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
As of November 17, 2019, NIELS ERIK JESPERSEN HOLDING ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 5%.
On September 13, 2019, the company changed its name from Renoguard ApS to AKI Therapeutics ApS.
AKI Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK -4,600, and the net result was DKK -4,608.
AKI Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK -4,000, and the net result was DKK -13,401.
As of February 5, 2018, Beier Holding ApS is registered as an owner of AKI Therapeutics A/S with an ownership share of 10%.
AKI Therapeutics A/S has published its interim report for the period March 1, 2016 – December 31, 2016.
As of April 28, 2016, KALLERMANN REVISION A/S STATSAUTORISERET REVISIONSFIRMA has been appointed auditor of AKI Therapeutics A/S.
As of April 28, 2016, Torsten Bjørn is registered as director of AKI Therapeutics A/S.
As of April 28, 2016, Peter Andreas Stakemann has stepped down as director of AKI Therapeutics A/S.
On April 28, 2016, the company changed its name from ApS STM nr. 4310 to Renoguard ApS.
As of March 1, 2016, Peter Andreas Stakemann is registered as director of AKI Therapeutics A/S.
AKI Therapeutics A/S was founded on March 1, 2016.
Companies in the same industry and area
CVR 30082346
CVR 36494433
CVR 39161672
CVR 41489189
CVR 44807866
